Puechal et al. Serial ANCA testing may predict relapse in a large group of AAV patients but is NOT useful for individual patients. @RheumNow #ACR24 Abstr#0721 https://t.co/ClvTk2Tlar https://t.co/k4vc7l9jzK

• Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis wit…
• https://x.com/RichardPAConway/status/1857827722002571721/photo/1

Quinn @KQuinnRheum @petercgrayson et al. FDG-PET is not particularly useful in monitoring GCA on tocilizumab. Toc reduces but often not eliminate PET inflammation. PET activity does not predict relapse or vascular progression @RheumNow #ACR24 Abstr#0742 https://t.co/1qcJCGV118 https://t.co/6mBCgcbYo6

• Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteriti…
• https://x.com/RichardPAConway/status/1857817152751022439/photo/1

Harkins @DrTrishHarkins et al. Serum disease activity markers in PMR. ROC analysis for active vs remission - fibrinogen (1.000), ESR (0.986), Haptoglobin (0.976), CRP (0.986), ALP (0.854). @RheumNow #ACR24 Abstr#0741 https://t.co/f8cX68Ov9Y https://t.co/zp5c7aQwxr

• Serum Markers of Disease Activity in Polymyalgia Rheumatica - ACR Meeting Abstr…
• https://x.com/RichardPAConway/status/1857816146097119682/photo/1

TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/pKa4U5L2fW https://t.co/MjzE14SeGi

• A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose…
• https://x.com/RichardPAConway/status/1857810106181718508/photo/1

More evidence: persistence of imaging abnormalities is probably NOT an adequate metric of LVV tx failure Boiardi et al - 87% TAK/LV-GCA pt w persistent dz on imaging despite clinical remission, TAK>GCA PET avidity more persistent in GCA @RheumNow #ACR24 Abstract 1617

SELECT-GCA Trial results show UPA 15 mg + 26-week GC taper leads to 46% sustained remission vs. 29% with placebo + 52-week taper (P=.0019). UPA15 reduced GC use (median 1615mg vs. 2882mg, P<.0001) and improved fatigue scores. Key finding: UPA15 combined with a 26-week GC… https://t.co/rdHU3GuOwc https://t.co/oMS7x46sIB

• https://x.com/i/web/status/1857803311363002426
• https://x.com/synovialjoints/status/1857803311363002426/photo/1

Upadacitinib (UPA), a new oral treatment option for GCA? Dr. Peter Merkel discusses SELECT-GCA. UPA15 + 26-week GC taper >> PBO with a 52-week GC taper for GCA remission. #ACR24 #ACRBest @RheumNow ABST#0770 https://t.co/UbQLVA8X7r

• https://x.com/JihaRheum/status/1857796768035213421/photo/1

Major update in tx for GCA beyond Toci SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission with SHORTER (26wk) steroid use compared to placebo (52wk) No significant adverse safety signal w JAKi including MACE/malignancy @RheumNow #ACR24 Abstract 0770 https://t.co/45D0Txed2N

• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1
• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1

Results from SELECT-GCA ➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W GC taper ➡️No new safety signals Is UPA the new kid on the block in #GCA? Ab0770 #ACRBest #ACR24 @RheumNow https://t.co/pHzozYiid5

• https://x.com/DrMiniDey/status/1857796013395697830/photo/1